News: MDxHealth SA (MDXH.BR)

MDXH.BR on Brussels Stock Exchange

10 Jul 2014
Price Change (% chg)

€-0.09 (-2.48%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Search Stocks
Select another date:

Tue, May 13 2014

BRIEF-MDxHealth signs co-marketing agreement for prostate cancer test

* MDxHealth and American Pathology Partners announce marketing agreement for ConfirmMDx for prostate cancer Source text for Eikon: Further company coverage:

BRIEF-MDXhealth signs co-marketing agreement with Long Island pathology

* Has entered into a co-marketing agreement with LI path (long island pathology, inc.) to promote MDXhealth's confirmmdx for prostate cancer test

BRIEF-MDxHealth licensee gets FDA panel recommendation for approval of colorectal cancer screening test

* Mdxhealth licensee exact sciences receives fda panel recommendation for approval of colorectal cancer screening test

BRIEF-MDxHealth full-year revenue up 28 pct

BRUSSELS, Feb 27 - MDxHealth SA : * Q4 confirmmdx revenue increased from $0.4 million in 2012 to $1.2 million in

Belgium's MDxHealth signs U.S. deal for prostate cancer test

BRUSSELS, Feb 20 - Belgian cancer testing group MDxHealth said on Thursday it had signed an agreement with U.S. health organisation Prime Health Services, which will extend the access to its prostate cancer test to 144 million insured people.

BRIEF-MDxHealth notes positive results in study on aggressive prostate cancer

BRUSSELS, Feb 3 - MDxHealth SA : * Announced positive results from important study designed to identify patients with aggressive prostate cancer * Study results support strategy of leveraging epigenetics to improve diagnosis, treatment of prostate cancer patients

BRIEF-MDxHealth signs deal with Teva for commercialization of two cancer tests

BRUSSELS, Jan 23 - MDxHealth SA : * Announces agreement with Teva Pharmaceuticals for commercialization of two cancer tests in Israel * Three-year deal for commercialization of Confirmmdx for prostate cancer,

Select another date:
Search Stocks